2 completed, 1 terminated, 1 unknown. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Enteral Feeding Intolerance: new trials by email Literature Review of Enteral Feeding Intolerance trials Research Report on Enteral Feeding Intolerance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amoxicillin for Enteral Nutrition Intolerance in Pediatric Intensive Care Unit Amoxicillin, Placebo - Enteral Feeding Intolerance | Phase 2 / Phase 3 | Unknown | Sohag University | 90 | 2023-04-24 | 2023-04-26 |
| The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients Prucalopride, Metoclopramide - Enteral Feeding Intolerance | Phase 1 / Phase 2 | Completed | Ain Shams University | 70 | 2022-08-30 | 2024-04-12 |
| TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) TAK-954, Metoclopramide, Normal Saline - Critical Illness, Enteral Nutrition | Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 1 | 2018-08-25 | 2019-09-24 |
| A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance TD-8954, Metoclopramide - Enteral Feeding Intolerance | Phase 1 / Phase 2 | Completed | Takeda | 13 | 2014-01-01 | 2020-02-18 |
Critical Illness (1)
Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Metoclopramide (3) · 4-((4-((2-isopropyl-1H-benzoimidazole-4-carbonyl)amino)methyl)piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester (1) · Amoxicillin (1) · Saline Solution (1) · prucalopride (1)
Ain Shams University (1) · Millennium Pharmaceuticals, Inc. (1) · Sohag University (1) · Takeda (1)
Australia (2) · Egypt (2) · Canada (1) · United Kingdom (1) · United States (1)
Daniel Canafax, PharmD, FCCP (1) · Eman Elmokadem, PhD (1) · Safaa H Ali, MD, PhD (1)
PMID 31990087, PMID 39584139, PMID 40501446
2017 (1)